 |
|
|
|
 |
|
|
| Article 1 to 10 out of 21 concerning Celera Genomics
|
-
Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
(02/25/2008)
Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland.The test, known as CRS7, ...
-
Celera:Carriers of a Gene Variant are at Elevated risk of Coronary Heart Disease Which is Virtually Eliminated by Statin Therapy
(01/24/2008)
New studies in more than 30,000 individuals indicate that carriers of the KIF6 gene variant have up to a 55% increased risk of a coronary event
Celera, an Applera Corporation business, announced three publications reporting that a variant of the gene encoding kinesin-like protein 6 (KIF6) is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) ...
-
Celera and Collaborators Discover a Genetic Marker Associated with Severe Coronary Artery Disease
(06/18/2007)
Carriers of gene variant exhibit an approximate 3-fold increased risk of disease
Celera, an Applera Corporation business, and its collaborators at the Cleveland Clinic, University of California, San Francisco (UCSF), the Scripps Institute, and Queens University, Canada, announced the publication of a paper describing a novel ...
-
Celera and LabCorp Announce Licensing Agreement to Commercialize Breast Cancer Testing Essays
(04/27/2007)
Celera, an Applera Corporation business, and Laboratory Corporation of America(R) Holdings (LabCorp(R)) announced that they have signed an agreement granting LabCorp a license to Celera's breast cancer metastasis and estrogen/progesterone receptor ...
-
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test
(08/24/2006)
Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza ...
-
Celera Genomics and Medarex Establish Therapeutic Antibody Collaboration in Cancer
(06/26/2006)
Collaboration Combines Celera's Protein Discoveries with Medarex's Expertise in Developing Fully Human Antibody Therapeutics
Celera Genomics, an Applera Corporation business, and Medarex, Inc. formed a strategic collaboration to discover and develop fully human antibodies for the potential treatment of multiple cancer indications. The collaboration will encompass the ...
-
Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks
(05/15/2006)
Celera Genomics, an Applera Corporation business, the University of California, San Francisco (UCSF), Cleveland Clinic, Case Western Reserve University and Brigham Young University, announced a publication describing two novel genetic markers ...
-
Applera and Beckman Coulter Announce Terms of Settlement of Legal Disputes regarding PCR technology
(04/28/2006)
Applera Corporation and Beckman Coulter, Inc. jointly announced that they have established the terms of a settlement to resolve all outstanding legal disputes between the parties regarding claims to certain Beckman Coulter patented capillary ...
-
Abbott Has Selected Two Additional Cancer Targets From Celera Genomics For Further Development
(02/20/2006)
Seven Celera Genomics Antigens Now in Research Pipeline with Partners
Celera Genomics Group, an Applera Corporation business, announced that Abbott has selected two Celera antigen targets for further investigation and potential therapeutic development. These are in addition to the two targets Abbott selected for ...
-
Celera Genomics Acquires Full Ownership of Celera Diagnostics Joint Venture
(01/11/2006)
Celera Genomics to Partner or Sell Small Molecule Drug Development Programs
Applera Corporation announced that its Board of Directors has approved a restructuring of its Celera Diagnostics joint venture, whereby, effective January 1, 2006, Celera Genomics acquired Applied Biosystems' 50 percent interest in the joint venture ...
|
|
|
|
|
Top
